Research · Sep 3, 2026
[OSCR] Oscar Health Thesis 2026: A Tech-First ACA Insurer Inflects to Sustainable Profitability
Oscar Health Inc (NYSE: OSCR), headquartered in New York City, is a tech-first US health-insurance company providing Individual + Family ACA-marketplace plans + Small Group plans + Medicare Advantage residuals + +Oscar B2B tech-services platform. Founded in 2012 by Mario Schlosser (CEO 2012-2023) + Joshua Kushner (Thrive Capital + Co-Founder) + Kevin Nazemi (left 2017) in New York City — explicitly-positioned as a tech-first ACA-marketplace-focused insurance company post-ACA-passage-2010 + first-cohort of ACA-marketplace insurers (alongside Bright Health/defunct, Clover Health/CLOV, Centene/Ambetter, Anthem/Elevance ACA). March 2021 Oscar IPO'd on NYSE at $39/share (~$7.9B-valuation) raising ~$1.4B; share-price declined 2022-2023 to ~$3-7 range reflecting sustained-operating-losses + 90%+ MLR + cash-burn + selectively-distressed-trading. 2023-2024 turnaround: Mark Bertolini CEO appointment April 2023 (prior Aetna CEO 2010-2018 sold to CVS for $69B in 2018), strategic-pivot to ACA-focus + exit Medicare-Advantage-loss-markets, MLR-improvement to ~80-84% from ~90%+ trough, adjusted-EBITDA-profitability achieved 2024, GAAP-profitability-inflection 2024-2025. Under President & CEO Mark Bertolini (CEO since April 2023, longtime US healthcare-insurance industry-veteran with Aetna scale-and-margin-playbook), FY2025 closes with selected various aggregate premium revenue ~$9.0-10.0B (~25-35% YoY growth), membership ~1.6-1.8M lives, MLR ~80-84%, adjusted EBITDA ~$0.30-0.45B (first sustainable profitability), adjusted EPS ~$0.65-1.20, and ~250M shares outstanding. The first deep-dive — Individual + Family ACA-marketplace insurance franchise — covers Oscar's dominant business pillar providing ACA Individual + Family health-insurance plans to ~1.6-1.8M members distributed through Healthcare.gov federally-facilitated-marketplace + state-based-exchange platforms (Covered California, New York State of Health, New Jersey GetCovered, others) in ~20 US states (Florida largest, plus Texas, Georgia, Tennessee, Ohio, NY, NJ, CA, AZ, IL, MI, MO, NC, SC, IA, KS, KY, NE, OK, PA, VA). Membership trajectory: ~0.5M end-2020 → ~1.0M end-2022 → ~1.0M end-2023 → ~1.4M end-2024 → ~1.6-1.8M end-2025 accelerated by ARPA subsidy extension (ARPA 2021), IRA subsidy extension through 2025, Medicaid-redetermination 2023-2024 (post-COVID-PHE-end driving ~20-25M+ Medicaid-loss with ~30-40% migrating to ACA), and Oscar's competitive-positioning. Competitive moat: (i) tech-first platform architecture (proprietary cloud-native insurance-operations from inception 2012 vs legacy mainframe), (ii) member-engagement (Oscar app + concierge-care-teams + virtual-care + care-coordination), (iii) provider-network design (narrow-network + value-based-care + primary-care-gatekeeper improving MLR), (iv) ACA-marketplace-specific underwriting + actuarial-discipline. MLR trajectory: ~90%+ 2022 → ~85-88% 2023 → ~82-85% 2024 → ~80-84% 2025 recovered via pricing-discipline + provider-network rationalization + care-management + utilization-management. FY2026 catalyst is ACA enrollment continuity + MLR maintenance + operating-leverage scaling + ACA-subsidy-policy navigation. Competes with Centene (CNC most-direct ACA-scale comp via Ambetter ~3.5-4M ACA members), Elevance Health (ELV ACA + commercial + Medicaid + MA diversified), Molina Healthcare (MOH Medicaid + ACA + MA), Humana (HUM ACA + MA + commercial), UnitedHealth Group (UNH dominant diversified), CVS Health/Aetna (CVS), Cigna (CI), BCBS-affiliated state-Blues; in tech-first health-insurance Clover Health (CLOV MA tech-first), Bright Health (defunct lessons-learned), Devoted Health (private), Alignment Healthcare (ALHC); in +Oscar B2B-platform Health Catalyst (HCAT), Cotiviti (private). The second deep-dive — +Oscar B2B + Small-Group + Medicare-Advantage residuals + multi-decade compounder thesis — covers +Oscar B2B tech-services platform (technology-platform-licensing providing Oscar's tech-stack — member-engagement + care-coordination + claims-administration + benefit-design — to other-insurers + provider-groups + self-insured-employers; Cigna partnership announced as anchor-customer 2022 but selectively-paused/wound-down 2023-2024; selectively-pre-commercial at scale but positioned for future-licensing as legacy-insurers seek cloud-native modernization), Small-Group plans (smaller segment), and Medicare Advantage residuals (selectively-exited some MA markets 2024-2025 reflecting MA-margin-pressure from v28-risk-adjustment-model + STAR-ratings-pressure + utilization-elevated 2023-2024 + Oscar-strategic-focus on ACA core). Multi-decade compounder thesis combines tech-platform structural-margin-advantage (cloud-native ops-stack scales at fixed-cost vs legacy variable-cost = operating-leverage compounding with membership), ACA-marketplace structural-growth (US uninsured rate declined from ~17% to ~8-9% via ACA-and-Medicaid-expansion + ACA-marketplace-membership grew from ~6M 2014 to ~21M 2024), Mark Bertolini operational-credibility + Aetna scale-and-margin-playbook, +Oscar B2B optionality, and founder-and-insider alignment (Joshua Kushner + Thrive Capital substantial-Class-B-voting-equity + Mario Schlosser co-founder continued board-and-advisory-role). Capital position is net-cash, no-dividend, growth-and-profitability-pivot: net cash + investment portfolio ~$1.5-2.0B (substantial-cash-and-investment-portfolio from prior-IPO-proceeds + ongoing-cash-generation), no meaningful credit-leverage (selectively-debt-free), ~$1.5-2.0B invested predominantly in IG fixed-income + Treasury-and-agency-securities generating ~$70-100M+ annual investment income, state-insurance-subsidiaries maintain well-above state-insurance-RBC requirements, ACA-required MLR ≥80%/Individual + ≥85%/Group with refunds below thresholds, FCF selectively-positive from 2024+, no regular dividend, minimal buybacks at this stage, ~250M shares total (Class A + Class B Founder-Insider-supervoting with Joshua Kushner + Thrive Capital ~50%+ voting power). At ~$13-19 per share, equity value ~$3.2-4.8B, EV ~$1.2-3.3B (net-cash-adjusted), ~13-25x EPS and ~3-9x EV/EBITDA. Base case: ACA-subsidy-extension + membership ~1.8-2.1M + revenue $10.5-12B + MLR ~82-84% + adjusted EBITDA $0.45-0.60B + EPS $1.00-1.50 + ~15-25% return. Bull case: subsidy-extension + accelerated membership + +Oscar B2B inflects + MLR improves to ~78-81% + EBITDA-margin ~5-6% + EPS $1.50-2.20 + re-rate 20-30x + 30-60%+ return. Bear case: subsidy-sunset post-2025 + membership-declines + revenue $8.5-9.5B + EPS $0.30-0.60 + de-rate 8-12x + ~30-50% downside.